|
EP3619215A1
|
|
Process to convert crude ascomycin into purified pimecrolimus
|
|
AU2018100567A4
|
|
Kit for administration of medicaments
|
|
IES20180139A2
|
|
Kit for administration of medicaments
|
|
FR3080613A3
|
|
Medication administration kit
|
|
EP3315151A1
|
|
Kit for administration of medicaments
|
|
CA2864876A1
|
|
Pharmaceutical formulations
|
|
AU2012200449A1
|
|
Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
|
|
DE102011103347A1
|
|
Nasal pharmaceutical formulation
|
|
NZ568349A
|
|
Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
|
|
AU2006224842A1
|
|
The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
|
|
EP1713473A1
|
|
The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
|
|
CA2550848A1
|
|
Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
|
|
AU2005210086A1
|
|
Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
|
|
NZ548302A
|
|
Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
|
|
US7553858B2
|
|
Combination of flupirtine and tramadol
|
|
NZ538020A
|
|
Novel combination of glucocorticoids and PDE-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and COPD
|
|
PL332595A1
|
|
Enatiomerically pure basic arylocycloalkyl hydroxycarboxylic esters, method obtaining them and their application a therapeutic agents
|
|
AT500684A1
|
|
Use of sweat carboxylic acids for the manufacture of a medicament for combating diseases of retroviruses
|
